文献速递白血病

RSK2是Pim2的新靶点,在FLT3-ITD阳性急性髓系白血病中具有促生存功能

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
PubMed 文献 · Leukemia · 2017-09-15

该研究在Pim2敲低的FLT3-ITD急性髓系白血病(AML)细胞中进行高通量转录组和蛋白质组分析,发现Pim2主要通过Bax表达和线粒体破坏控制凋亡,并鉴定RSK2为Pim2新靶点;异位表达RPS6KA3等位基因可挽救Pim2敲低细胞的活力,RPS6KA3敲低可减少人AML细胞在小鼠体内的传播。

要点

  • Pim2在FLT3-ITD AML中主要通过Bax表达和线粒体破坏调控凋亡。
  • RSK2被鉴定为Pim2的新靶点,异位表达RPS6KA3可挽救Pim2敲低细胞的活力。
  • RPS6KA3敲低可减少人AML细胞在小鼠体内的传播。

核心结论

  • RSK2是Pim2的新靶点,在FLT3-ITD AML中具有转化治疗潜力。

研究设计与样本

  • 在Pim2敲低的FLT3-ITD AML细胞中进行高通量转录组和蛋白质组分析,并在小鼠体内进行RPS6KA3敲低实验。

主要发现

  • Pim2主要通过Bax表达和线粒体破坏控制凋亡。
  • RSK2(由RPS6KA3基因编码的90 kDa丝氨酸/苏氨酸激酶)被鉴定为Pim2新靶点。
  • 异位表达RPS6KA3等位基因可挽救Pim2敲低细胞的活力。
  • RPS6KA3敲低可减少人AML细胞在小鼠体内的传播。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • Pim在FLT3-ITD下游的精确生物学功能需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) with the FLT3 internal tandem duplication (FLT3-ITD AML) accounts for 20-30% of AML cases. This subtype usually responds poorly to conventional therapies, and might become resistant to FLT3 tyrosine kinase inhibitors (TKIs) due to molecular bypass mechanisms. New therapeutic strategies focusing on resistance mechanisms are therefore urgently needed. Pim kinases are FLT3-ITD oncogenic targets that have been implicated in FLT3 TKI resistance. However, their precise biological function downstream of FLT3-ITD requires further investigation. We performed high-throughput transcriptomic and proteomic analyses in Pim2-depleted FLT3-ITD AML cells and found that Pim2 predominantly controlled apoptosis through Bax expression and mitochondria disruption. We identified ribosomal protein S6 kinase A3 (RSK2), a 90 kDa serine/threonine kinase involved in the mitogen-activated protein kinase cascade encoded by the RPS6KA3 gene, as a novel Pim2 target. Ectopic expression of an RPS6KA3 allele rescued the viability of Pim2-depleted cells, supporting the involvement of RSK2 in AML cell survival downstream of Pim2. Finally, we showed that RPS6KA3 knockdown reduced the propagation of human AML cells in vivo in mice. Our results point to RSK2 as a novel Pim2 target with translational therapeutic potential in FLT3-ITD AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hospital MA, Jacquel A, Mazed F, et al. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. Leukemia. 2017. PMID: 28914261. doi:10.1038/leu.2017.284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。